SOCIAL SUPPORT AND TREATMENT OUTCOME OF OBSESSIVE-COMPULSIVE DISORDER AT 9-MONTH FOLLOW-UP

被引:83
作者
STEKETEE, G
机构
来源
BEHAVIOURAL PSYCHOTHERAPY | 1993年 / 21卷 / 02期
关键词
D O I
10.1017/S014134730001805X
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The present study investigated whether social support and family members' reactions to clients with obsessive compulsive disorder played a significant role in the follow-up outcome of an intensive behavioral treatment program. The roles OCD symptoms, moodstate, social functioning and life events were also assessed. General social support did not predict relapse, but significant others' empathy and positive interactions were associated with maintenance of gains. Negative family interactions (especially criticism and anger) and belief that clients could control their symptoms predicted relapse. Higher levels of post-treatment anxiety and depression and poorer functioning were related to negative outcome, as was distress from life events during follow-up. Results are discussed with respect to possible mechanisms of action and future research needs.
引用
收藏
页码:81 / 95
页数:15
相关论文
共 34 条
[21]  
KAZDIN AE, 1978, EVALUATION BEHAVIOR
[22]   CLOMIPRAMINE AND EXPOSURE FOR OBSESSIVE-COMPULSIVE RITUALS .1. [J].
MARKS, IM ;
STERN, RS ;
MAWSON, D ;
COBB, J ;
MCDONALD, R .
BRITISH JOURNAL OF PSYCHIATRY, 1980, 136 (JAN) :1-25
[23]  
MASH EJ, 1980, IMPROVING LONG TERM
[24]  
MAVISSAKALIAN M, 1985, AM J PSYCHIAT, V142, P572
[26]   PARTNER SUPPORT AND RELAPSE IN SMOKING-CESSATION PROGRAMS [J].
MERMELSTEIN, R ;
LICHTENSTEIN, E ;
MCINTYRE, K .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1983, 51 (03) :465-466
[27]   IS FOLLOW-UP NECESSARY IN EVALUATING PSYCHOTHERAPY [J].
NICHOLSON, RA ;
BERMAN, JS .
PSYCHOLOGICAL BULLETIN, 1983, 93 (02) :261-278
[28]   RECENT ADVANCES IN BEHAVIORAL MEASUREMENT OF OBSESSIONAL ILLNESS - DIFFICULTIES COMMON TO THESE AND OTHER MEASURES [J].
PHILPOTT, R .
SCOTTISH MEDICAL JOURNAL, 1975, 20 :33-40
[29]  
SPIELBERGER ED, 1970, STATE TRAIT ANXIETY
[30]  
STEELE GP, 1980, PSYCHOL MED, V1, P301